Acute Mountain Sickness
Conditions
Interventions
Coenzyme Q10 10mg, group:Give coenzyme Q10 10mg
groupacetazolamide group:Give Acetazolamide
Coenzyme Q10 20mg group:Give coenzyme Q10 20mg
Sponsors
Second People's Hospital of Haibei Tibetan Autonomous Prefecture, Qinghai Province
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. All participants were healthy, non-smoking adults who had not adapted to high altitude. 2. Age between 18 and 55 years of age, living at an altitude below 1,000 feet (about 305) The age limit was set to reduce the potential hidden collusion of older participants and heart disease risk, because of plans to do daily, exhausting workouts at high altitudes. 3. Participants also need to pass drug screening and physical examination, and have a normal base before enrollment laboratory indicators (hematology, clinical biochemistry, and urinalysis).
Exclusion criteria
Exclusion criteria: 1. The main exclusion criteria include a history of cardiovascular, cerebrovascular, respiratory, renal, hepatic or other major comorbidities; 2. Blood oxygen saturation (SpO2) is less than 95% at sea level; 3. Surgery, blood donation, or any drug treatment within 14 days prior to screening and the study period; 4. Patients who are currently taking anxiolytic drugs (including selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, benzodiazepines, etc.); 5. Canadian Cardiovascular Association (CCS) grade 4 stable angina; 6. Uncontrolled hypertension (systolic blood pressure >180mmHg or diastolic blood pressure >100mmHg) despite ongoing antihypertensive therapy; 7. New York Heart Association (NYHA) Class III or IV heart failure; 8. Patients with coronary heart disease combined with atrial fibrillation; 9. Clinically significant complications, including hepatic insufficiency (ALT or AST levels are more than 2 times higher than normal), renal impairment (serum creatinine levels are more than 2 times higher than normal), severe cardiopulmonary insufficiency, pulmonary hypertension, chronic obstructive pulmonary disease, history of cerebral hemorrhage or epilepsy, and patients requiring anticonvulsant drugs; 10. Patients with myocardial infarction or grade 4 angina pectoris three months before the start of the research project; 11. Patients with chest pain confirmed by examination to be in the acute stage of acute coronary syndrome and rheumatic heart disease, dilated heart disease, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, biliary heart syndrome, gastric and esophageal reflux, hiatal hernia, aortic dissection pulmonary embolism, mediastinal hematoma and other clear causes; 14. Patients with a history of specific bleeding, or a history of bleeding caused by taking warfarin; 12. Those who have suffered from hematopoietic system diseases in the past; 13. Those who have had surgery and bleeding tendency in the past 4 weeks (excluding PCI); Patients who participated in any other clinical study or took its investigational drug within 14, 90 days; 15. Those who are known or suspected to be allergic to the drugs in this study or have allergies; 16. Drug abusers. Patient has a recent (past 2 years) history of alcohol abuse or known drug dependence; 17. Mentally ill patients; 18. Patients who are judged by the doctor to be unable to participate in the study; 19. The patient is a family member or relative of the staff of the research center.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| degree of blood oxygen saturation;Lake Louise Questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood pressure;heart rate;height;weight;breathing rate;Destination height; climbing speed;Scheduled stay time; | — |
Countries
China
Contacts
Public ContactLiming Chen
Second People's Hospital of Haibei Tibetan Autonomous Prefecture, Qinghai Province
Outcome results
None listed